Clinical trial

A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)

NCT06593522

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention anvumetostat Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)

Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2024-12-26

PhasePHASE2

Conditions

MTAP-deleted NSCLCunresolved

Interventions

anvumetostatDRUG

Sponsors & collaborators

Amgenlead sponsor

Mapped research locations

Los AngelesCalifornia, United States3 DallasTexas, United States2 NashvilleTennessee, United States2 BeijingChina2 PragueCzechia2 IstanbulTurkey (Türkiye)2 HangzhouZhejiang, China2 AnkaraTurkey (Türkiye)2 SingaporeSingapore2 São PauloSão Paulo, Brazil2 Porto AlegreRio Grande do Sul, Brazil2 DuarteCalifornia, United States2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06593522 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.